Full Press Release Details
Life Sciences Announces Findings from Intranasal Anti-CD3 mAb Treatment in Intracerebral Hemorrhage at the Annual American Academy of
Neurology Conference
YORK, April 27, 2023 -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology
company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced broad-based findings on
the utility of nasal anti-CD3 mAb in the treatment of intracerebral hemorrhage (ICH). The data using a mouse model of collagenase-induced
ICH was presented at the Annual American Academy of Neurology conference. The full presentation can be viewed at https://www.aan.com/MSA/Public/Events/AbstractDetails/52974
L. Weiner, M.D., Chairman of Tiziana's Scientific Advisory Board and Co-Director of the Ann Romney Center for Neurologic Diseases at
Brigham and Women's Hospital, a founding member of Mass General Brigham Healthcare System, stated, "Intracerebral hemorrhages
are the deadliest form of acute stroke with early mortality ranging from 30% to 40%. It has been well demonstrated that microglial activation
and edema play a critical role in the morbidity and mortality of this devastating event."
Izzy, M.D., MBCHB., Neurocritical Care faculty at Brigham and Women's Hospital and Assistant Professor of Neurology at Harvard
Medical School and presenter of the study at AAN, commented, "Currently, there are no effective interventions for ICH. Our research
studied the effect of an intranasal anti-CD3 antibody in a mouse model of induced ICH. I believe that intranasal anti-CD3 represents
a novel therapeutic approach for treating ICH as well as potentially other types of acute brain injury."
the study demonstrated that intranasal anti-CD3 antibody:1
comprehensive and consistent findings of Dr. Izzy's research strongly supports the promising role of intranasal foralumab, the
only fully human anti-CD3 monoclonal antibody (mAb), and its potential for broad applications in neuroinflammation, including the treatment
of acute ICH," said Gabriele Cerrone, Executive Chairman, Founder, and interim Chief Executive Officer of Tiziana. "These
exciting findings may allow Tiziana to explore additional intranasal foralumab neuroinflammatory indications to help patients with unmet
needs and create further shareholder value".
T cells play an important role in the inflammatory process. Foralumab, the only fully human anti-CD3 monoclonal antibody (mAb), binds
to the T cell receptor and dampens inflammation by modulating T cell function, thereby suppressing effector features in multiple immune
cell subsets. This effect has been demonstrated in patients with COVID and with multiple sclerosis, as well as in healthy normal subjects.
Intranasal foralumab Phase 2 trials are expected to start in the third quarter of 2023 in patients with non-active SPMS. Immunomodulation
by nasal anti-CD3 mAb represents a novel avenue for treatment of inflammatory human diseases.2
Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery
technologies to enable alternative routes of immunotherapy. Tiziana's innovative nasal approach has the potential to provide an
improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana's lead candidate,
intranasal foralumab, which is the only fully human anti-CD3 mAb, has demonstrated a favorable safety profile and clinical response in
patients in studies to date. Tiziana's technology for alternative routes of immunotherapy has been patented with several applications
pending and is expected to allow for broad pipeline applications.
Spencer, Business Development and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
LifeSci Advisors, LLC